ASH 2017 - Prof dr. Verstovsek

Prof dr. Verstovsek geeft een weergave van de studie: "Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)", die tijdens de ASH is gepresenteerd.
 

0119HEM1103327
×

Ask Speakers

×

Medical Information Request